Drugs / MAGE-A3-DP4
last change Apr 2014 re-read 2 minutes ago

MAGE-A3-DP4

Developed for
melanoma
Investigated by
Centre Hospitalier Universitaire Vaudois · Immutep S.A.S.

Trials 1 · a red edge is where a trial was stopped

201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT01308294 Jun 2010 → Apr 2014 melanoma Centre Hospitalier Universitaire Vaudois Terminated No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MAGE-A3-DP4 “syringe 2 containing Melan-A and MAGE-A3-DP4 peptides with IMP321/LAG-3 ± Montanide” NCT01308294